Advertisement

Laser Treatment of MEDICATION-Related Osteonecrosis of the Jaws

  • Paolo VescoviEmail author
Chapter
  • 45 Downloads

Abstract

MRONJ is a multifactorial disease, and it is therefore difficult to realize an aetiological therapy.

MRONJ management is controversial: there are no evidence-based guidelines in the literature, in particular with regard to surgical procedures possibly associated with good results during a long-term follow-up.

The literature recommends a conservative treatment as initial therapy for pain control and elimination of acute inflammatory signs before any surgical option, for all stages of disease.

Laser applications at low intensity (low-level laser therapy—LLLT) have been reported in the literature for the treatment of MRONJ. Biostimulant effects of laser improve reparative process, increase inorganic matrix of bone and osteoblast mitotic index and stimulate lymphatic and blood capillary growth. It has been reported that LLLT has anti-inflammatory actions and it can help to control pain as well. LLLT also holds biostimulatory properties with favourable actions on bacterial control and wound healing. The review of the literature confirmed the superiority of the LLLT association with antibiotic therapy in comparison to other noninvasive approach to MRONJ management.

In our experience, more than 60% of MRONJ patients treated with laser biostimulation and antibiotic therapy (2 g of amoxicillin and 1 g of metronidazole a day for 2 weeks) have had improvement of their symptomatology, and 35% have had complete mucosal healing during 6 months of follow-up.

This therapy is easy to administer and useful also for aged and compromised patients, and it is not associated with any known side effect.

A soft surgical approach performed with laser, in patients unresponsive to antibiotic therapy or LLLT, represents a good solution: it is rapid and poorly invasive and can be performed under local anaesthesia in day-surgery regimen. The erbium-doped yttrium aluminium garnet (Er:YAG) laser has emerged as a possible alternative to conventional methods of bone ablation as the main components of bone have a high absorption of laser light at the wavelength of 2.94 μm. The histological findings of bone treated with erbium laser highlighted vital lamellar bone at the lased margins without microscopic evidence of inflammation or osteoclastic activity. Some recent researches reported that Er:YAG laser irradiation stimulates the secretion of platelet-derived growth factor in osteotomy sites and has bactericidal effect against Actinomyces and anaerobes. Results confirm that the laser surgery represents the best therapeutic option for minimally invasive treatment of the early stages of the disease also in immunocompromised patients.

The association of the Er:YAG laser and autofluorescence examination seems to be highly useful in removing additional minimal necrotic bone after osteoplasty. It is possible to use laser evaporation in areas in which absence of fluorescence or hypofluorescence has been revealed. Moreover, the previously cited biological advantages of Er:YAG surgery combined with the biomodulation of the soft and hard tissues induced by LLLT seem to integrate a valid approach for MRONJ treatment.

Keywords

MEDICATION-related osteonecrosis of the jaw (MRONJ) Low-level laser therapy (LLLT) Laser jaw bone surgery Erbium laser Diode laser Nd:YAG laser 

References

  1. 1.
    Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–7.CrossRefGoogle Scholar
  2. 2.
    Ruggiero SL, Dodson TB, Fantasia J, Goodday R, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–56.CrossRefGoogle Scholar
  3. 3.
    Hoefert S, Yuan A, Munz A, Grimm M, et al. Clinical course and therapeutic outcomes of operatively and non-operatively managed patients with denosumab-related osteonecrosis of the jaw (DRONJ). J Craniomaxillofac Surg. 2017;45(4):570–8.  https://doi.org/10.1016/j.jcms.2017.01.013.CrossRefPubMedGoogle Scholar
  4. 4.
    Wynn RL. Bevacizumab (Avastin): an anti-angiogenic drug associated with osteonecrosis of the jaw. Gen Dent. 2011;59(6):410–3.PubMedGoogle Scholar
  5. 5.
    Fusco V, Porta C, Saia G, Paglino C, et al. Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an italian multicenter study and review of the literature. Clin Genitourin Cancer. 2015;13(4):287–94.CrossRefGoogle Scholar
  6. 6.
    Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg. 2005;63:1567–75.CrossRefGoogle Scholar
  7. 7.
    Solomon DH, Mercer E, Woo SB, Avorn J, et al. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int. 2013;24:237–44.CrossRefGoogle Scholar
  8. 8.
    Pichardo SE, van Merkesteyn JP. Bisphosphonate related osteonecrosis of the jaws: spontaneous or dental origin ? Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116(3):287–92.CrossRefGoogle Scholar
  9. 9.
    Hinson AM, Smith CW, Siegel ER, Stack BC. Is bisphosphonate-related osteonecrosis of the jaw an infection? A histological and microbiological ten-year summary. Int J Dent. 2014;2014:452737.  https://doi.org/10.1155/2014/452737.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Gallegro L, Junquera L. Consequence of therapy discontinuation in bisphosphonate-associated osteonecrosis of the jaws. Br J Oral Maxillofac Surg. 2009;47(1):67–8.CrossRefGoogle Scholar
  11. 11.
    Vescovi P, Nammour S. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) therapy. A critical review. Minerva Stomatol. 2010;59(4):181–213.PubMedGoogle Scholar
  12. 12.
    Bermúdez-Bejarano EB, Serrera-Figallo MA, Gutiérrez-Corrales A, Romero-Ruiz MM, et al. Prophylaxis and antibiotic therapy in management protocols of patients treated with oral and intravenous bisphosphonates. J Clin Exp Dent. 2017;9(1):e141–9.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Kühl S, Walter C, Acham S, Pfeffer R, Lambrecht JT. Bisphosphonate-related osteonecrosis of the jaws—a review. Oral Oncol. 2012;48(10):938–47.CrossRefGoogle Scholar
  14. 14.
    Ripamonti CI, Cislaghi E, Mariani L, Maniezzo M. Efficacy and safety of medical ozone (O3) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: preliminary results of a phase I-II study. Oral Oncol. 2011;47:185–90.CrossRefGoogle Scholar
  15. 15.
    Freiberger JJ. Utility of Hyperbaric Oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(suppl 1):96–106.CrossRefGoogle Scholar
  16. 16.
    Vescovi P, Meleti M, Merigo E, Manfredi M. Bisphosphonate-associated osteonecrosis (BON) of the jaws: a possible treatment? J Oral Maxillofac Surg. 2006;05:012.Google Scholar
  17. 17.
    Karu T. Mitochondrial mechanisms of photobiomodulation in context of new data about multiples roles of ATP. Photomed Laser Surg. 2010;28(2):159–60.CrossRefGoogle Scholar
  18. 18.
    Belletti S, Uggeri J, Mergoni G, Vescovi P, Merigo E, Fornaini C, Nammour S, Manfredi M, Gatti R. Effects of 915 nm GaAs diode laser on mitochondria of human dermal fibroblasts: analysis with confocal microscopy. Lasers Med Sci. 2015;30:375–81.CrossRefGoogle Scholar
  19. 19.
    McGee-Lawrence ME, Bradley EW, Dudakovic A, Carlson SW, Ryan ZC, Kumar R, Dadsetan M, Yaszemski MJ, Chen Q, An K-N, Westendorf JJ. Histone deacetylase 3 is required for maintenance of bone mass during aging. Bone. 2013;52:296–307.CrossRefGoogle Scholar
  20. 20.
    Doeuk C, Hersant B, Bosc R, Lange F, SidAhmed-Mezi M, et al. Current indication for low level laser treatment in maxillo-facial surgery. Br J Oral Maxillofac Surg. 2015;53(4):309–15.CrossRefGoogle Scholar
  21. 21.
    Basso FG, Turrioni AP, Soares DG, Bagnato VS, Hebling J, de Souza Costa CA. Low-level laser therapy for osteonecrotic lesions: effects on osteoblasts treated with zoledronic acid. Support Care Cancer. 2014;22(10):2741–8.CrossRefGoogle Scholar
  22. 22.
    Pansani TN, Basso FG, Turirioni AP, Kurachi C, Hebling J, de Souza Costa CA. Effects of low-level laser therapy on the proliferation and apoptosis of gingival fibroblasts treated with zoledronic acid. Int J Oral Maxillofac Surg. 2014;43(8):1030–4.CrossRefGoogle Scholar
  23. 23.
    Walter C, Pabst AM, Ziebart T. Effects of a low-level diode laser on oral keratinocytes, oral fibroblasts, endothelial cells and osteoblasts incubated with bisphosphonates: an in vitro study. Biomed Rep. 2015;3(1):14–8.CrossRefGoogle Scholar
  24. 24.
    Mergoni G, Vescovi P, Sala R, Merigo E, Passerini P, Maestri R, Corradi D, Govoni P, Nammour S, Bianchi MG. The effect of laser therapy on the expression of osteocalcin and osteopontin after tooth extraction in rats treated with zoledronate and dexamethasone. Support Care Cancer. 2016;24(2):807–13.CrossRefGoogle Scholar
  25. 25.
    Romeo U, Galanakis A, Marias G, Del Vecchio A, Tenore G, Palaia G, Vescovi P, Polimeni A. Observation of pain control in patients with bisphosphonate-induced osteonecrosis using low level laser therapy: preliminary results. Photomed Laser Surg. 2011;29(7):447–52.CrossRefGoogle Scholar
  26. 26.
    Vescovi P, Merigo E, Meleti M, Fornaini C, Nammour S, Manfredi M. Nd:YAG laser biostimulation of bisphosphonate-associated necrosis of the jawbone with or without surgical treatment. Br J Oral Maxillofac Surg. 2007;45(8):628–32.CrossRefGoogle Scholar
  27. 27.
    Vescovi P, Merigo E, Manfredi M, Meleti M, Fornaini C, Bonanini M, Rocca JP, Nammour S. Nd:YAG laser biostimulation in the treatment of Bisphosphonate-associated osteonecrosis of the jaws (BON): experience in 26 cases. Photomed Laser Surg. 2008;26(1):37–46.CrossRefGoogle Scholar
  28. 28.
    Weber JB, Camilotti RS, Ponte ME. Efficacy of laser therapy in the management of bisphosphonate-related osteonecrosis of the jaw(BRONJ): a systematic review. Lasers Med Sci. 2016;31(6):1261–72.CrossRefGoogle Scholar
  29. 29.
    Latifyan S, Genot MT, Klastersky J. Bisphosphonate-related osteonecrosis of the jaw: a review of the potential efficacy of low-level laser therapy. Support Care Cancer. 2016;24(9):3687–93.CrossRefGoogle Scholar
  30. 30.
    Vescovi P, Merigo E, Meleti M, Manfredi M. Early surgical approach preferable to medical therapy for bisphosphonates related osteonecrosis of the jaw. J Oral Maxillofac Surg. 2008;66:931–3.CrossRefGoogle Scholar
  31. 31.
    Urade M, Tanaka N, Furusawa K, Shimada J, et al. National survey for bisphosphonate-related osteonecrosis of the jaws in Japan. J Otal Maxillofac Surg. 2011;69:364–71.CrossRefGoogle Scholar
  32. 32.
    Wutzl A, Pohl S, Sulzbacher I, Seemann R, Lauer G, Ewers R, Drach J, Klug C. Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws. Head Neck. 2012;34(2):194–200.CrossRefGoogle Scholar
  33. 33.
    Graziani F, Vescovi P, Campisi G, Favia G, et al. Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retrospective survey of 347 cases. J Oral Maxillofac Surg. 2012;70(11):2501–7.CrossRefGoogle Scholar
  34. 34.
    Caldroney S, Ghazali N, Dyalram D, Lubek JE. Surgical resection and vascularized bone reconstruction in advanced stage medication-related osteonecrosis of the jaw. Int J Oral Maxillofac Surg. 2017;46(7):871–6.CrossRefGoogle Scholar
  35. 35.
    Stübinger S. Advances in bone surgery: the Er:YAG laser in oral surgery and implant dentistry. Clin Cosmet Investig Dent. 2010;2:47–62.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Pourzarandian A, Watanabe H, Aoki A, Ichinose S, Sasaki KM, Nitta H, et al. Histological and TEM examination of early stages of bone healing after Er:YAG laser irradiation. Photomed Laser Surg. 2004;22(4):342–50.CrossRefGoogle Scholar
  37. 37.
    Poutzarandian A, Watanabe H, Ruwanpura M, Aoki A, Noguchi K, Ishikawa I. Er:YAG laser irradiation increase prostaglandin E2 production via the induction of cyclooxygenase-2 mRNA in human gingival fibroblasts. J Periodontol Res. 2005;40:182–6.CrossRefGoogle Scholar
  38. 38.
    Romeo U, Del Vecchio A, Palaia G, Tenore G, Visca P, Maggiore C. Bone damage induced by different cutting instruments—an in vitro study. Braz Dent J. 2009;20(2):162–8.CrossRefGoogle Scholar
  39. 39.
    Papadaki M, Doukas A, Farinelli WA, Kaban L, Troulis M. Vertical ramus osteotomy with Er:YAG laser: a feasibility study. Int J Oral Maxillofac Surg. 2007;36(12):1193–7.CrossRefGoogle Scholar
  40. 40.
    Baek K-W, Deibel W, Marinov D, Griessen M, Dard M, Bruno A, et al. A comparative investigation of bone surface after cutting with mechanical tools and Er:YAG laser. Lasers Surg Med. 2015;47(5):426–32.CrossRefGoogle Scholar
  41. 41.
    Gabrić D, Blašković M, Gjorgijevska E, Mladenov M, Tašič B, Jurič IB, et al. Evaluation of bone healing after osteotomies prepared with Er:YAG laser in contact and noncontact modes and piezosurgery—an animal study. J Oral Maxillofac Surg. 2016;74(1):18–28.Google Scholar
  42. 42.
    Kesler G, Shvero DK, Tov YS, Romanos G. Platelet derived growth factor secretion and bone healing after Er:YAG laser bone irradiation. J Oral Implantol. 2011;37:195–204.CrossRefGoogle Scholar
  43. 43.
    Sennhenn-Kirchner S, Schwarz P, Schliephake H, Konietschke F, Brunner E, Borg-von ZM. Decontamination efficacy of erbium:yttrium-aluminium-garnet and diode laser light on oral Candida albicans isolates of a 5-day in vitro biofilm model. Lasers Med Sci. 2009;24(3):313–20.CrossRefGoogle Scholar
  44. 44.
    Aoki A, Mizutani K, Shwarz F, Sculean A, et al. Periodontal and peri-implant wound healing following laser therapy. Periodontol. 2000;2015(68):217–69.Google Scholar
  45. 45.
    Vescovi P, Merigo E, Manfredi M, Meleti M, Fornaini C, Bonanini M, Rocca JP, De Moor RJ, Nammour S. Surgical treatment of maxillary osteonecrosis due to bisphosphonates using an Er:YAG (2940 nm) laser. Discussion of 17 clinical cases. Rev Belg Med Dent. 2009;64(2):87–95.Google Scholar
  46. 46.
    Angiero F, Sannino C, Borloni R, Crippa R, Benedicenti S, Romanos GE. Osteonecrosis of the jaws caused by bisphosphonates: evaluation of a new therapeutic approach using the Er:YAG laser. Lasers Med Sci. 2009;24:849–56.CrossRefGoogle Scholar
  47. 47.
    Stübinger S, Dissmann J-P, Pinho NC, Saldamli B, et al. A preliminary report about treatment of bisphosphonate related osteonecrosis of the jaw with Er:YAG ablation. Lasers Surg Med. 2009;41:26–30.CrossRefGoogle Scholar
  48. 48.
    Rugani P, Acham S, Truschnegg A, et al. Bisphosphonate-associated osteonecrosis of the jaws: surgical treatment with ErCrYSGG-laser. Case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(6):e1–6.CrossRefGoogle Scholar
  49. 49.
    Vescovi P, Manfredi M, Merigo E, Meleti M, Fornaini C, Rocca JP, Nammour S. Surgical approach with Er:YAG laser on Osteonecrosis of the Jaws (ONJ) in patients under Bisphosphonate Therapy (BPT). Lasers Med Sci. 2010;25(1):101–13.CrossRefGoogle Scholar
  50. 50.
    Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour S. Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. J Oral Pathol Med. 2012;41(3):214–21.CrossRefGoogle Scholar
  51. 51.
    Holzinger D, Seeman R, Klug C, Ewers R, et al. Long-term success of surgery in bisphosphonate-related osteonecrosis of the jaw (BRONJs). Oral Oncol. 2013;49:66–70.CrossRefGoogle Scholar
  52. 52.
    Gabriele M, La Ferla F, Cei S, Nisi M, Graziani F. Conservative surgical treatment in the management of BRONJ: a case series of 129 consecutive cases. Ann Stomatol. 2013;4(Suppl 2):18.Google Scholar
  53. 53.
    Vescovi P, Manfredi M, Merigo E, Guidotti R, Meleti M, Pedrazzi G, Fornaini C, Bonanini M, Ferri T, Nammour S. Early surgical laser-assisted management of bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 101 treated sites with long-term follow-up. Photomed Laser Surg. 2012;30(1):5–13.CrossRefGoogle Scholar
  54. 54.
    Ruggiero SL. Emerging concepts in the management and treatment of osteonecrosis of the jaw. Oral Maxillofac Surg Clin North Am. 2013;25(1):11–20.CrossRefGoogle Scholar
  55. 55.
    Vescovi P, Merigo E, Meleti M, Manfredi M, Fornaini C, Nammour S, Mergoni G, Sarraj A, Bagan JV. Conservative surgical management of stage I bisphosphonate-related osteonecrosis of the jaw. Int J Dent. 2014;2014:107690.  https://doi.org/10.1155/2014/107690.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P, Di Lenarda R, Biasotto M. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol. 2014;50(11):1049–57.CrossRefGoogle Scholar
  57. 57.
    Pautke C, Tischer T, Neff A, Horch HH, Kolk A. In vivo tetracycline labeling of bone: an intraoperative aid in the surgical therapy of osteoradionecrosis of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:e10–3.CrossRefGoogle Scholar
  58. 58.
    Assaf AT, Zrnc TA, Riecke B, et al. Intraoperative efficiency of fluorescence imaging by Visually Enhanced Lesion Scope (VELscope) in patients with bisphosphonate related osteonecrosis of the jaw (BRONJ). J Craniomaxillofac Surg. 2014;42:e157–64.CrossRefGoogle Scholar
  59. 59.
    Hoell T, Huschak G, Beier A, et al. Auto fluorescence of intervertebral disc tissue: a new diagnostic tool. Eur Spine J. 2006;15(Suppl 3):S345.CrossRefGoogle Scholar
  60. 60.
    Ristow O, Pautke C. Auto-fluorescence of the bone and its use for delineation of bone necrosis. Int J Oral Maxillofac Surg. 2014;43(11):1391–3.CrossRefGoogle Scholar
  61. 61.
    Ristow O, Otto S, Troeltzsch M, Hohlweg-Majert B, Pautke C. Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ). J Craniomaxillofac Surg. 2015;43(2):290–3.CrossRefGoogle Scholar
  62. 62.
    Vescovi P, Giovannacci I, Otto S, Manfredi M, Merigo E, Fornaini C, Nammour S, Meleti M. Medication-Related Osteonecrosis of the Jaws: an auto-fluorescence guided surgical approach performed with Er:YAG laser. Photomed Laser Surg. 2015;33(8):437–42.CrossRefGoogle Scholar
  63. 63.
    Giovannacci I, Meleti M, Manfredi M, Merigo E, Fornaini C, Bonanini M, Vescovi P. Autofluorescence as indicator for detecting the surgical margins of medication-related osteonecrosis of the jaws. Minerva Stomatol. 2016;65(4):248–52.PubMedGoogle Scholar
  64. 64.
    Giovannacci I, Meleti M, Corradi D, Vescovi P. Clinical differences in autofluorescence between viable and nonvital bone: a case report with histopathologic evaluation performed on medication-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2017;75(6):1216–22.  https://doi.org/10.1016/j.joms.2016.12.011.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Unit of Oral Medicine and Laser Surgery, Department of Medicine and SurgeryUniversity Center of Dentistry, University of ParmaParmaItaly

Personalised recommendations